Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $30.7 million.

  • Seres Therapeutics' Non Operating Income rose 23625.71% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year increase of 74188.75%. This contributed to the annual value of -$14.1 million for FY2024, which is 38401.45% down from last year.
  • Per Seres Therapeutics' latest filing, its Non Operating Income stood at $30.7 million for Q3 2025, which was up 23625.71% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Non Operating Income ranged from a high of $59.9 million in Q1 2025 and a low of -$22.5 million during Q3 2024
  • Moreover, its 5-year median value for Non Operating Income was -$285000.0 (2021), whereas its average is $4.3 million.
  • As far as peak fluctuations go, Seres Therapeutics' Non Operating Income crashed by 73055.17% in 2024, and later soared by 380345.28% in 2025.
  • Over the past 5 years, Seres Therapeutics' Non Operating Income (Quarter) stood at -$356000.0 in 2021, then crashed by 37.36% to -$489000.0 in 2022, then soared by 571.78% to $2.3 million in 2023, then soared by 206.76% to $7.1 million in 2024, then surged by 333.53% to $30.7 million in 2025.
  • Its Non Operating Income was $30.7 million in Q3 2025, compared to $5.0 million in Q2 2025 and $59.9 million in Q1 2025.